Based on overwhelming evidence implicating CCL2/CCR2 in (experimental) pulmonary fibrosis, a trial with carlumab, an anti-CCL2 antibody was conducted in IPF. The gene discussed is CCL2; the disease is idiopathic pulmonary fibrosis.